You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Hero image
Gemini 1 and 2 infographics

Gemini Study 96 week IAS slides

GEMINI 96 week infographic

Gemini Study 96 week IAS slides

GEMINI 96 week infographic

  • Efficacy

    POWERFUL EFFICACY IN TREATMENT-NAÏVE ADULT

    RAPID, POWERFUL AND DURABLE EFFICACY

    DOVATO Non-Inferior to DTG + TDF/FTC at 96 Weeks 1

    POWERFUL EFFICACY IN TREATMENT-NAÏVE ADULT

    Efficacy graph

    ITT–E Snapshot analysis.

    Adapted from Cahn et al, 2019. 1

  • Baseline Viral Load Strata

    POWERFUL SUPPRESSION ACROSS VIRAL LOAD STRATA

    Virological Outcomes by Baseline Viral Load at 96 Weeks (ITT–E Pooled Analysis) 1

    Baseline viral load strata

    DTG 50 mg + 3TC 300 mg used in the GEMINI studies.

    Adapted from Cahn et al, 2019. 1

  • Viral Blips

    ROBUST VIROLOGICAL CONTROL COMPARABLE TO DTG + TDF/FTC

    Similar Viral Blip* Frequencies Across Both Arms Through Week 48 2

    Viral blips

    Adapted from Cahn et al, 2019. 1

    • Proportion of patients with viral blips was similar across both arms: 12% (83/716) in DOVATO vs 13% (93/717) in DTG + TDF/FTC 2

    DTG 50 mg + 3TC 300 mg used in the GEMINI studies.

    *A viral blip is a transient increase in viral load ≥50 copies/mL to <200 copies/mL bounded by viral loads <50 copies/mL. Note: individual patients could have had ≥1 blip.

Virological Outcomes by Baseline CD4+ T-cell Count Strata at 96 Weeks 1

  • ITT-E: >200 cells/mm2 DOVATO 88% (573/653) vs DTG + TDF/FTC 90% (594/662) 
  • When treatment-related discontinuation=failure (TRDF)* analysis is applied: >200 cells/mm2  DOVATO 97% (633/653) vs DTG + TDF/FTC 96% (638/662) 
  • ITT-E: ≤200 cells/mm3 DOVATO 68% (43/63) vs DTG + TDF/FTC 87% (48/55) 
  • When TRDF analysis is applied: ≤200 cells/mm3 DOVATO 94% (59/63) vs DTG + TDF/FTC 96% (53/55)

References:

  1. Cahn P, Sierra Madero J, Arribas J, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infections: 96-week results from the GEMINI studies, Presented at: International AIDS Conference; July 21-24, 2019; Mexico City, Mexico, Slides WEAB0404LB.
  2. Underwood M, Wang R, Horton J, et al. Dolutegravir (DTG) plus lamivudine (3TC) versus DTG plus tenofovir/emtricitabine (TDF/FTC) fixed-dose combination in the GEMINI studies-viral load rebound including 'blips' through 48 weeks. Presented at: International AIDS Conference ; July 21-24, 2019; Mexico City, Mexico. Poster MOPEB231.
  3. Dovato Summary of Product Characteristics. Available at www.medicines.ie. Last Accessed June 2020

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse reactions can also be reported to the HPRA by calling (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.